181 related articles for article (PubMed ID: 34956093)
1. Lipidomics Reveals Serum Specific Lipid Alterations in Diabetic Nephropathy.
Xu T; Xu X; Zhang L; Zhang K; Wei Q; Zhu L; Yu Y; Xiao L; Lin L; Qian W; Wang J; Ke M; An X; Liu S
Front Endocrinol (Lausanne); 2021; 12():781417. PubMed ID: 34956093
[TBL] [Abstract][Full Text] [Related]
2. ApoM/HDL-C and apoM/apoA-I ratios are indicators of diabetic nephropathy in healthy controls and type 2 diabetes mellitus.
Zhang P; Gao J; Pu C; Feng G; Wang L; Huang L; Zhang Y
Clin Chim Acta; 2017 Mar; 466():31-37. PubMed ID: 28073663
[TBL] [Abstract][Full Text] [Related]
3. Osteoinductive factor is a novel biomarker for the diagnosis of early diabetic nephropathy.
Wang S; Wang Y; Zheng R; Zhao Z; Ma Y
Int J Clin Exp Pathol; 2015; 8(3):3110-5. PubMed ID: 26045825
[TBL] [Abstract][Full Text] [Related]
4. Growth arrest-specific protein 6 (Gas6) as a noninvasive biomarker for early detection of diabetic nephropathy.
Li W; Wang J; Ge L; Shan J; Zhang C; Liu J
Clin Exp Hypertens; 2017; 39(4):382-387. PubMed ID: 28513288
[TBL] [Abstract][Full Text] [Related]
5. Circulating hsa-miR-221 as a possible diagnostic and prognostic biomarker of diabetic nephropathy.
Abdel-Tawab MS; Mohamed MG; Doudar NA; Rateb EE; Reyad HR; Elazeem NAA
Mol Biol Rep; 2023 Dec; 50(12):9793-9803. PubMed ID: 37831346
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on an integrated biomarker system.
Huang M; Liang Q; Li P; Xia J; Wang Y; Hu P; Jiang Z; He Y; Pang L; Han L; Wang Y; Luo G
Mol Biosyst; 2013 Aug; 9(8):2134-41. PubMed ID: 23719966
[TBL] [Abstract][Full Text] [Related]
7. Association of ANGPTL8 and Resistin With Diabetic Nephropathy in Type 2 Diabetes Mellitus.
Li M; Fan R; Peng X; Huang J; Zou H; Yu X; Yang Y; Shi X; Ma D
Front Endocrinol (Lausanne); 2021; 12():695750. PubMed ID: 34603198
[TBL] [Abstract][Full Text] [Related]
8. Study the Association of Tumor Necrosis Factor Promoter Polymorphism with Type 2 Diabetic Nephropathy.
Emara M; El-Edel R; Fathy WM; Aboelkhair NT; Watany MM; Abou-Elela DH
Mediators Inflamm; 2020; 2020():1498278. PubMed ID: 32684830
[TBL] [Abstract][Full Text] [Related]
9. Significance of serum miR-29a in the occurrence and progression of diabetic nephropathy: A cross-sectional study.
Liu Q; Wang M; Xu T; Liang W; Yang F
J Clin Lab Anal; 2022 Feb; 36(2):e24210. PubMed ID: 34964177
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Serum Micro-RNA 152-3p in Type 2 Diabetes Mellitus with a Significant Elevation in Progressive Nephropathy.
Nasser M; Ibrahim KMF; Elnabawi WM; Ahmed TM
Egypt J Immunol; 2020 Jun; 27(2):81-92. PubMed ID: 33548980
[TBL] [Abstract][Full Text] [Related]
11. ALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy.
Sulaj A; Kopf S; Gröne E; Gröne HJ; Hoffmann S; Schleicher E; Häring HU; Schwenger V; Herzig S; Fleming T; Nawroth PP; von Bauer R
J Diabetes Complications; 2017 Jun; 31(6):1058-1065. PubMed ID: 28325697
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin and periostin in early detection and progression of diabetic nephropathy: epithelial-to-mesenchymal transition.
El-Dawla NMQ; Sallam AM; El-Hefnawy MH; El-Mesallamy HO
Clin Exp Nephrol; 2019 Aug; 23(8):1050-1057. PubMed ID: 31104272
[TBL] [Abstract][Full Text] [Related]
13. Expression Level of Circulating Cell Free miR-155 Gene in Serum of Patients with Diabetic Nephropathy.
Akhbari M; Khalili M; Shahrabi-Farahani M; Biglari A; Bandarian F
Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414764
[TBL] [Abstract][Full Text] [Related]
14. Serum ApoA4 levels predicted the progression of renal impairment in T2DM.
Cheng CW; Chang CC; Chen HW; Lin CY; Chen JS
Eur J Clin Invest; 2018 Jun; 48(6):e12937. PubMed ID: 29675916
[TBL] [Abstract][Full Text] [Related]
15. Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: Differential expression profile of circulating lncRNA
.
Yang Y; Lv X; Fan Q; Wang X; Xu L; Lu X; Chen T
Clin Nephrol; 2019 Jul; 92(1):25-35. PubMed ID: 31079598
[TBL] [Abstract][Full Text] [Related]
16. Identification of Urinary Metabolite Biomarkers of Type 2 Diabetes Nephropathy Using an Untargeted Metabolomic Approach.
Chen CJ; Liao WL; Chang CT; Lin YN; Tsai FJ
J Proteome Res; 2018 Nov; 17(11):3997-4007. PubMed ID: 30265543
[TBL] [Abstract][Full Text] [Related]
17. Assessment of two novel renal tubular proteins in type 2 diabetic patients with nephropathy.
Abdel Ghafar MT; Shalaby KH; Okda HI; Abo El Gheit RE; Soliman NA; Keshk WA
J Investig Med; 2020 Mar; 68(3):748-755. PubMed ID: 31722957
[TBL] [Abstract][Full Text] [Related]
18. Significance of glycated LDL in different stages of diabetic nephropathy.
Siddiqui K; George TP; Nawaz SS; Yaslam M; Almogbel E; Al-Rubeaan K
Diabetes Metab Syndr; 2019; 13(1):548-552. PubMed ID: 30641763
[TBL] [Abstract][Full Text] [Related]
19. Decreased Urine miR-199-3p may be a Potential Biomarker for Diabetic Nephropathy via Targeting Zinc Finger E-box-Binding Protein 1.
Meng L; Li G; Liu X; Jiang J; Zhu M; Sun Y
Clin Lab; 2018 Jul; 64(7):1177-1182. PubMed ID: 30146830
[TBL] [Abstract][Full Text] [Related]
20. Plasma lipidomics reveals potential lipid markers of major depressive disorder.
Liu X; Li J; Zheng P; Zhao X; Zhou C; Hu C; Hou X; Wang H; Xie P; Xu G
Anal Bioanal Chem; 2016 Sep; 408(23):6497-507. PubMed ID: 27457104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
